News ASCO26: Verzenio gives hope of liposarcoma treatment advance The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.
News Boehringer moves liposarcoma drug into pivotal trial Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with l
News Ex-BioNTech execs launch 'AI-native' cancer company Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.